218 related articles for article (PubMed ID: 30095976)
21. Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex.
Liu F; Lunsford EP; Tong J; Ashitate Y; Gibbs SL; Yu J; Choi HS; Henske EP; Frangioni JV
PLoS One; 2012; 7(6):e38589. PubMed ID: 22719903
[TBL] [Abstract][Full Text] [Related]
22. Surfactant dysfunction and lung inflammation in the female mouse model of lymphangioleiomyomatosis.
Atochina-Vasserman EN; Guo CJ; Abramova E; Golden TN; Sims M; James ML; Beers MF; Gow AJ; Krymskaya VP
Am J Respir Cell Mol Biol; 2015 Jul; 53(1):96-104. PubMed ID: 25474372
[TBL] [Abstract][Full Text] [Related]
23. Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells.
Himes BE; Obraztsova K; Lian L; Shumyatcher M; Rue R; Atochina-Vasserman EN; Hur SK; Bartolomei MS; Evans JF; Krymskaya VP
PLoS One; 2018; 13(5):e0197105. PubMed ID: 29758070
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex.
Kovalenko A; Sanin A; Kosmas K; Zhang L; Wang J; Akl EW; Giannikou K; Probst CK; Hougard TR; Rue RW; Krymskaya VP; Asara JM; Lam HC; Kwiatkowski DJ; Henske EP; Filippakis H
Cancer Res; 2021 Apr; 81(8):2086-2100. PubMed ID: 33593821
[TBL] [Abstract][Full Text] [Related]
25. Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.
Steagall WK; Pacheco-Rodriguez G; Glasgow CG; Ikeda Y; Lin JP; Zheng G; Moss J
Am J Pathol; 2013 Sep; 183(3):938-50. PubMed ID: 23867796
[TBL] [Abstract][Full Text] [Related]
26. [
Verwer EE; Kavanagh TR; Mischler WJ; Feng Y; Takahashi K; Wang S; Shoup TM; Neelamegam R; Yang J; Guehl NJ; Ran C; Massefski W; Cui Y; El-Chemaly S; Sadow PM; Oldham WM; Kijewski MF; El Fakhri G; Normandin MD; Priolo C
Clin Cancer Res; 2018 Dec; 24(23):5925-5938. PubMed ID: 30054282
[TBL] [Abstract][Full Text] [Related]
27. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
[TBL] [Abstract][Full Text] [Related]
28. Metastasis of benign tumor cells in tuberous sclerosis complex.
Henske EP
Genes Chromosomes Cancer; 2003 Dec; 38(4):376-81. PubMed ID: 14566858
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin II receptor type 1 blockade regulates Klotho expression to induce TSC2-deficient cell death.
Shrestha S; Adib E; Imani J; Aguiar DJ; Lamattina AM; Tassew DD; Henske EP; Perrella MA; Priolo C; El-Chemaly S
J Biol Chem; 2022 Nov; 298(11):102580. PubMed ID: 36220392
[TBL] [Abstract][Full Text] [Related]
30. Lymphangioleiomyomatosis and tuberous sclerosis complex.
Chorianopoulos D; Stratakos G
Lung; 2008; 186(4):197-207. PubMed ID: 18408969
[TBL] [Abstract][Full Text] [Related]
31. Role of the CXCR4/CXCL12 axis in lymphangioleiomyomatosis and angiomyolipoma.
Clements D; Markwick LJ; Puri N; Johnson SR
J Immunol; 2010 Aug; 185(3):1812-21. PubMed ID: 20585037
[TBL] [Abstract][Full Text] [Related]
32. [Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].
She Y; Pan X; Xing YF; Zhou T; Zhang ZL; Shi MH; Chen YJ
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):886-892. PubMed ID: 27998463
[No Abstract] [Full Text] [Related]
33. Targeting SPHK1/S1PR3-regulated S-1-P metabolic disorder triggers autophagic cell death in pulmonary lymphangiomyomatosis (LAM).
Li F; Zhang Y; Lin Z; Yan L; Liu Q; Li Y; Pei X; Feng Y; Han X; Yang J; Zheng F; Li T; Zhang Y; Fu Z; Shao D; Yu J; Li C
Cell Death Dis; 2022 Dec; 13(12):1065. PubMed ID: 36543771
[TBL] [Abstract][Full Text] [Related]
34. TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.
Lesma E; Ancona S; Sirchia SM; Orpianesi E; Grande V; Colapietro P; Chiaramonte E; Di Giulio AM; Gorio A
J Cell Mol Med; 2014 May; 18(5):766-79. PubMed ID: 24606538
[TBL] [Abstract][Full Text] [Related]
35. Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.
Kristof AS; You Z; Han YS; Giaid A
Peptides; 2010 Aug; 31(8):1511-6. PubMed ID: 20433884
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
37. Clinical and molecular insights into lymphangioleiomyomatosis.
Steagall WK; Taveira-DaSilva AM; Moss J
Sarcoidosis Vasc Diffuse Lung Dis; 2005 Dec; 22 Suppl 1():S49-66. PubMed ID: 16457017
[TBL] [Abstract][Full Text] [Related]
38. Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.
Prizant H; Sen A; Light A; Cho SN; DeMayo FJ; Lydon JP; Hammes SR
Mol Endocrinol; 2013 Sep; 27(9):1403-14. PubMed ID: 23820898
[TBL] [Abstract][Full Text] [Related]
39. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.
Jiang ZB; Wang WJ; Xu C; Xie YJ; Wang XR; Zhang YZ; Huang JM; Huang M; Xie C; Liu P; Fan XX; Ma YP; Yan PY; Liu L; Yao XJ; Wu QB; Lai-Han Leung E
Cancer Lett; 2021 Sep; 515():36-48. PubMed ID: 34052328
[TBL] [Abstract][Full Text] [Related]
40. Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration.
Chebib N; Archer F; Bobet-Erny A; Leroux C; Cottin V
Sci Rep; 2018 Oct; 8(1):14698. PubMed ID: 30279475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
